Inovio Pharmaceuticals
About: Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Employees: 134
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,018% more call options, than puts
Call options by funds: $436K | Put options by funds: $39K
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
22% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 27
3% more funds holding
Funds holding: 104 [Q4 2024] → 107 (+3) [Q1 2025]
0.07% more ownership
Funds ownership: 37.02% [Q4 2024] → 37.09% (+0.07%) [Q1 2025]
9% less capital invested
Capital invested by funds: $24.5M [Q4 2024] → $22.2M (-$2.3M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
247%
upside
Avg. target
$7.67
432%
upside
High target
$13
803%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Piper Sandler Edward Tenthoff | 247%upside $5 | Overweight Initiated | 9 Jul 2025 |
RBC Capital Gregory Renza | 247%upside $5 | Sector Perform Reiterated | 14 May 2025 |
Oppenheimer Jay Olson | 803%upside $13 | Outperform Maintained | 14 May 2025 |
Financial journalist opinion
Based on 4 articles about INO published over the past 30 days
Neutral
PRNewsWire
3 weeks ago
INOVIO to Present at Upcoming Scientific Conference
PLYMOUTH MEETING, Pa. , July 7, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting on the potential of next generation DNA medicine technology in rare disease at the upcoming Orphan Drug Summit in Boston, Massachusetts.
Neutral
PRNewsWire
3 weeks ago
INOVIO Announces Pricing of $25 Million Public Offering
PLYMOUTH MEETING, Pa. , July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock and accompanying Series A warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock and Series B warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock, at a combined public offering price of $1.75 per share of common stock and accompanying Series A and Series B warrants.
Neutral
PRNewsWire
4 weeks ago
INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa. , July 2, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying Series A warrants and Series B warrants to purchase shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof), in an underwritten public offering.
Neutral
GlobeNewsWire
4 weeks ago
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development.
Neutral
Seeking Alpha
2 months ago
Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2025 Financial Results Conference Call.
Negative
Zacks Investment Research
2 months ago
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago.
Neutral
PRNewsWire
2 months ago
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25 Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025 INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgery Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAbs) were well tolerated and exhibited long-lasting in vivo production Preprint manuscript available on ResearchSquare.com PLYMOUTH MEETING, Pa. , May 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2025 and provided an update on recent company developments.
Neutral
Seeking Alpha
2 months ago
Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ET Company Participants Jacqui Shea - President and CEO Mike Sumner - Chief Medical Officer Conference Call Participants Roy Buchanan - JMP Roy Buchanan All right. Thank you again, everybody, for joining us here at the Citizens Life Sciences Conference.
Neutral
PRNewsWire
3 months ago
INOVIO to Present at Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa. , April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York.
Neutral
PRNewsWire
3 months ago
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
PLYMOUTH MEETING, Pa. , April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025.
Charts implemented using Lightweight Charts™